EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase

Huimin Zhang, Dounan Xu, Hongchan Huang, Hao Jiang, Linghao Hu, Liping Liu, Ge Sun, Jing Gao, Yuanqing Li, Cuicui Xia, Shijie Chen, Hu Zhou iD und 3 weitere

ACS Chemical Biology · 19.04.2024 · 19 (4) · 999-1010

DOI: 10.1021/acschembio.4c00048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 21.03.2024. Verfasst von Huimin Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528437, China. Hauptthemen laut MEDLINE: CSK Tyrosine-Protein Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Chinese Polar Environment Comprehensive Investigation and Assessment Programmes, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonreceptor tyrosine kinase c-Src plays a crucial role in cell signaling and contributes to tumor progression. However, the development of selective c-Src inhibitors turns out to be challenging. In our previous study, we performed posttranslational modification-inspired drug design (PTMI-DD) to provide a plausible way for designing selective kinase inhibitors. In this study, after identifying a unique pocket comprising a less conserved cysteine and an autophosphorylation site in c-Src as well as a promiscuous covalent inhibitor, chemical optimization was performed to obtain (R)-LW-Srci-8 with nearly 75-fold improved potency (IC50 = 35.83 ± 7.21 nM). Crystallographic studies revealed the critical C-F···C═O interactions that may contribute to tight binding. The kinact and Ki values validated the improved binding affinity and decreased warhead reactivity of (R)-LW-Srci-8 for c-Src. Notably, in vitro tyrosine kinase profiling and cellular activity-based protein profiling (ABPP) cooperatively indicated a specific inhibition of c-Src by (R)-LW-Srci-8. Intriguingly, (R)-LW-Srci-8 preferentially binds to inactive c-Src with unphosphorylated Y419 both in vitro and in cells, subsequently disrupting the autophosphorylation. Collectively, our study demonstrated the feasibility of developing selective kinase inhibitors by cotargeting a nucleophilic residue and a posttranslational modification site and providing a chemical probe for c-Src functional studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CSK Tyrosine-Protein KinaseProtein Kinase InhibitorsHumansPhosphorylationProtein-Tyrosine KinasesSignal Transductionsrc-Family Kinases

Substanzen

CSK Tyrosine-Protein KinaseProtein Kinase InhibitorsProtein-Tyrosine Kinasessrc-Family Kinases

Autor:innen und Institutionen

  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528437, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Department of Chemistry, College of Sciences, Shanghai University, Shanghai 200444, China.
  • Center for Chemical Biology and Drug Discovery, State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
  • University of Chinese Academy of Sciences (UCAS), 19 Yuquan Road, Beijing 100049, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.

ORCID-Profile: Hu Zhou, Xiangqian Kong, Cheng Luo

Förderung

  • Chinese Polar Environment Comprehensive Investigation and Assessment Programmes
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • The project of National Multidisciplinary Innovation Team of Traditional Chinese Medicine supported by National Administration of Traditional Chinese Medicine
  • Pearl River Talents Plan

Zitieren

APA

Zhang, H., Xu, D., Huang, H., Jiang, H., Hu, L., Liu, L., Sun, G., Gao, J., Li, Y., Xia, C., Chen, S., Zhou, H., Kong, X., Wang, M., & Luo, C. (2024). Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase. ACS Chemical Biology, 19(4), 999-1010. https://doi.org/10.1021/acschembio.4c00048

Vancouver

Zhang H, Xu D, Huang H, Jiang H, Hu L, Liu L, et al. Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase. ACS Chemical Biology. 2024;19(4):999-1010. doi:10.1021/acschembio.4c00048

BibTeX
@article{Zhang2024,
  author = {Zhang, Huimin and Xu, Dounan and Huang, Hongchan and Jiang, Hao and Hu, Linghao and Liu, Liping and Sun, Ge and Gao, Jing and Li, Yuanqing and Xia, Cuicui and Chen, Shijie and Zhou, Hu and Kong, Xiangqian and Wang, Mingliang and Luo, Cheng},
  title = {Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase},
  journal = {ACS Chemical Biology},
  year = {2024},
  volume = {19},
  number = {4},
  pages = {999--1010},
  doi = {10.1021/acschembio.4c00048}
}
Kostenlos starten →